IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

 

Notes

 

01.01.–30.06.2023

 

01.01.–30.06.2022

 

01.04.–30.06.2023

 

01.04.–30.06.2022

Operating income

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

17

 

 

17

 

Foreign exchange gains

 

 

 

500

 

780

 

 

60

Other income

 

 

 

5

 

3

 

 

 

 

 

 

522

 

783

 

17

 

60

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Net losses from securities

 

3

 

(246 320)

 

(510 645)

 

(3 106)

 

(222 239)

Finance expenses

 

 

 

(2 550)

 

(591)

 

(1 442)

 

(343)

Foreign exchange losses

 

 

 

 

 

(144)

 

Administrative expenses

 

6

 

(16 295)

 

(19 900)

 

(7 352)

 

(9 415)

Other expenses

 

 

 

(2 660)

 

(2 534)

 

(1 437)

 

(1 108)

 

 

 

 

(267 825)

 

(533 670)

 

(13 481)

 

(233 105)

Profit/(loss) before tax

 

7

 

(267 303)

 

(532 887)

 

(13 464)

 

(233 045)

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(30)

 

(39)

 

(14)

 

(20)

Profit/(loss) for the period

 

 

 

(267 333)

 

(532 926)

 

(13 478)

 

(233 065)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(267 333)

 

(532 926)

 

(13 478)

 

(233 065)

 

 

 

 

 

 

 

 

 

 

 

Income per share in CHF

 

8

 

(4.87)

 

(9.66)

 

(0.24)

 

(4.23)

Diluted income per share in CHF

 

8

 

(4.87)

 

(9.66)

 

(0.24)

 

(4.23)

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer